By Chris Wack
Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.
The biopharmaceutical company said icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor in adults with moderately to severely active ulcerative colitis.
Protagonist said the study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated. The study also demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12.
Icotrokinra had a response rate of 63.5% for patients treated with the highest dose at week 12, versus 27% for placebo. Clinical remission and response rates continued to improve through week 28.
Icotrokinra was well tolerated with the proportions of participants reporting one or more adverse events being similar between the icotrokinra dose groups and the placebo group.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 10, 2025 09:44 ET (13:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。